The Fms‐like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome
Open Access
- 29 October 2010
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 62 (11) , 3447-3456
Abstract
Objective: To determine if the Fms‐like tyrosine kinase 3 ligand (Flt‐3L), a cytokine implicated in B cell ontogenesis and proliferation in hematologic malignancies, might be responsible for the increased numbers of circulating Bm2 and Bm2′ B cell subsets in patients with primary Sjögren's syndrome (SS).Methods: Serum levels of Flt‐3L were measured in 64 patients with primary SS and in 20 healthy controls matched for age and sex. Flt‐3L and its receptor Flt‐3 were quantified in circulating B cells and in salivary gland (SG) biopsy tissues by immunofluorescence analysis. The effect of Flt‐3L on circulating B lymphocytes was then determined by coculture with cells of a human SG (HSG) epithelial cell line.Results: Serum levels of Flt‐3L were increased in patients with primary SS as compared with controls (mean ± SD 135.8 ± 5.5 versus 64.4 ± 4.5 pg/ml; P < 0.001). Serum levels of Flt‐3L in primary SS patients correlated with the numbers of Bm2 and Bm2′ cells (r = 0.46, P < 0.0006), and Flt‐3 was selectively expressed in Bm2 and Bm2′ cells. B cell culture experiments showed that Flt‐3L potentiated the proliferative effect of anti‐IgM stimulation. In SGs, we found that infiltrating B cells expressed Flt‐3 and epithelial cells produced Flt‐3L. Finally, Flt‐3L levels were associated with high disease activity scores and increased risk of developing lymphoma.Conclusion: Serum levels of Flt‐3L are elevated in patients with primary SS and correlate with abnormal B cell distribution. Flt‐3 is mainly expressed by Bm2 and Bm2′ cells. Serum levels of Flt‐3L might explain the clinical evolution of primary SS to B cell lymphoma that is observed in some patients, thus opening the possibility of new avenues for therapy.Keywords
This publication has 32 references indexed in Scilit:
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2010
- Is the blood B-cell subset profile diagnostic for Sjögren syndrome?Annals of the Rheumatic Diseases, 2009
- Intra-Articular Fms-Like Tyrosine Kinase 3 Ligand Expression Is a Driving Force in Induction and Progression of ArthritisPLOS ONE, 2008
- Sjögren’s SyndromeDrugs & Aging, 2008
- Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2007
- BAFF‐induced changes in B cell antigen receptor–containing lipid rafts in Sjögren's syndromeArthritis & Rheumatism, 2005
- Complementary Signaling through flt3 and Interleukin-7 Receptor α Is Indispensable for Fetal and Adult B Cell GenesisJournal of Experimental Medicine, 2003
- Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndromeArthritis & Rheumatism, 2002
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cellsCell, 1993